SNNMI Abstract of the Year: Targeted radionuclide treatment achieves high response rate, minimal toxicities for advanced-stage neuroendocrine tumors
Vancouver, British Columbia, Canada—A targeted radionuclide alpha therapy, 225Ac-DOTATATE, has been shown to have long-term anti-tumor effects in patients with ...